“…Figure depicts several drug molecules that contain a nicotinate scaffold, including dexamethasone isonicotinate (an anti‐inflammatory, anti‐allergic glucocorticoid), morniflumate (an analgesic, antipyretic and anti‐inflammatory agent), flunixin meglumin (a cyclooxygenase inhibitor), vitamin E nicotinate (an antioxidants), nicorandil (a vasodilatory drug), and hepronicate (a hypolipidemic drug) . To date, many of approaches have been successfully developed to produce nicotinate skeletons by employing electron‐deficient β ‐enamino esters ( β ‐EAEs) as the readily accessible C,N ‐dinucleophilic synthons combined with the condensation of 1,3‐dicarbonyl compounds, α,β ‐unsaturated ketones, alkynones, Mannich base hydrochlorides, and IBX‐mediated oxidative annulation of allylic alcohols (Scheme ) . However, most of these methods have been compromised by harsh reaction conditions, stoichiometric halogenated reagents, functionalized starting materials, which could not fulfill the requirements of reagent efficiency.…”